HMG CoA reductase inhibitors
Browse ingredients, then choose a strength and product. Ontario inventory only; not a treatment recommendation.
ROSUVASTATIN CALCIUM: products 61 to 80 of 80.
Prices below are the ministry's recorded amounts per source unit, not pharmacy quotes or the patient's payment. Different strengths, forms and package units are not directly comparable. The cost plan asks for quantity and refill details.
| Product / strength / form | Ontario listing | Recorded ministry price | Next step |
|---|---|---|---|
| Rosuvastatin 10mg TabDIN 02405636 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 10mg TabDIN 02411636 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 20mg TabDIN 02405644 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 20mg TabDIN 02411644 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 40mg TabDIN 02405652 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 40mg TabDIN 02411652 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 5mg TabDIN 02405628 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Rosuvastatin 5mg TabDIN 02411628 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Sandoz Rosuvastatin 10mg TabDIN 02338734 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Sandoz Rosuvastatin 20mg TabDIN 02338742 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Sandoz Rosuvastatin 40mg TabDIN 02338750 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Sandoz Rosuvastatin 5mg TabDIN 02338726 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Taro-Rosuvastatin 10mg TabDIN 02382652 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Taro-Rosuvastatin 20mg TabDIN 02382660 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Taro-Rosuvastatin 40mg TabDIN 02382679 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Taro-Rosuvastatin 5mg TabDIN 02382644 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Teva-Rosuvastatin 10mg TabDIN 02354616 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Teva-Rosuvastatin 20mg TabDIN 02354624 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Teva-Rosuvastatin 40mg TabDIN 02354632 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Teva-Rosuvastatin 5mg TabDIN 02354608 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
Not seeing a product? Search Canadian records by medication name or DIN. Absence from this Ontario extract does not establish non-coverage. Open an exact product for its dated Health Canada status; a listing is not a stock check.
Class sources and program rules
Ontario Ministry of Health: odb-formulary-ed43-extract-2026-08-26.xml, extract 2026-08-26. Ontario class index: formulary-ed43-front-matter.txt, Part V.
Products assigned to this ATC category in the held Health Canada records. Combinations assigned to other categories are not included; search their ingredient or product name separately.
C10AA HMG CoA reductase inhibitors. Health Canada DPD extract 2026-09-02.
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, 2026-01-20
C10AA HMG CoA reductase inhibitors